Thrombotic microangiopathies (TMAs) complicate ~20% of alloHSCT procedures, and although half of cases may resolve when GvHD immunoprophylaxis is discontinued, 3-year survival rates for those in whom the TMA persists are poor. Here, Jeffrey Laurence, MD, Weill Cornell Medical College, Greenwich, CT, discusses the analysis of the effect of defibrotide on endothelial injury induced by plasmas of patients with TMAs. An inhibitory effect was observed, indicating that defibrotide may represent an important resource for the treatment of TMA, although Dr Laurance highlights how further studies are required. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

свернуть